In late July, a reconstituted FDA advisory panel voted to recommend six peptides — BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon — for inclusion on the agency's 503A Bulk Drug Substances List, which governs what compounding pharmacies may legally prepare. The notable part isn't the list itself; it's who the panel overruled to get there. The FDA's own career scientists had unanimously recommended against adding these compounds, citing a near-total absence of human clinical safety data. Observers reportedly described an audible gasp in the room when the vote came back the opposite way.
The panel that delivered that vote looks different from the one that existed a year ago. Eight new members were added as part of a broader deregulatory push from HHS, and reporting has noted that most of the new appointees have financial ties to businesses that sell or administer peptides. Whatever the FDA ultimately decides — the agency must still choose whether to accept the panel's non-binding recommendation, a process that can take 12 to 24 months — the vote has reopened a debate that never really closed: these compounds still have no FDA-approved indications, no standardized dosing, and no established safety and efficacy record, regardless of where they land on a compounding list.
Enforcement, meanwhile, has become a patchwork. States like Florida, Texas, Nevada, and Arizona remain permissive, while New York, California, Connecticut, and Alabama have moved toward tighter oversight — including facility inspections, age restrictions, and in at least one case a court-ordered shutdown of a seller. In a separate but related move, the FDA has also restricted the ingredients used in mass-compounded semaglutide and tirzepatide and warned it will pursue enforcement against unapproved marketing that positions compounded products as "equivalent" to approved drugs.
None of this changes the fundamentals for the research community. A compound's regulatory classification says nothing about the purity or identity of the specific vial in front of you. As enforcement tightens unevenly across states and the gray market keeps growing around unmet consumer demand, third-party COA verification and transparent sourcing remain the only reliable way to know what you're actually studying — a point regulatory uncertainty doesn't change, and if anything, makes more important.
Source: The American Journal of Managed Care, "5 Things to Know About the FDA's Peptide Reversal," Aug. 21, 2026.
